pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-15a |
Genomic Coordinates | chr13: 50049119 - 50049201 |
Synonyms | MIRN15A, hsa-mir-15a, miRNA15A, MIR15A |
Description | Homo sapiens miR-15a stem-loop |
Comment | Reference . |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-15a-5p | ||||||||||||||||||
Sequence | 14| UAGCAGCACAUAAUGGUUUGUG |35 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
Circulating MicroRNA Expression Profiling | Circulating MicroRNA Expression Profiling |
---|
Gene Information | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CCND2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synonyms | KIAK0002, MPPH3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Description | cyclin D2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transcript | NM_001759 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expression | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Putative miRNA Targets on CCND2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3'UTR of CCND2 (miRNA target sites are highlighted) |
>CCND2|NM_001759|3'UTR 1 GGATGCCAGTTGGGCCGAAAGAGAGAGACGCGTCCATAATCTGGTCTCTTCTTCTTTCTGGTTGTTTTTGTTCTTTGTGT 81 TTTAGGGTGAAACTTAAAAAAAAAATTCTGCCCCCACCTAGATCATATTTAAAGATCTTTTAGAAGTGAGAGAAAAAGGT 161 CCTACGAAAACGGAATAATAAAAAGCATTTGGTGCCTATTTGAAGTACAGCATAAGGGAATCCCTTGTATATGCGAACAG 241 TTATTGTTTGATTATGTAAAAGTAATAGTAAAATGCTTACAGGAAAACCTGCAGAGTAGTTAGAGAATATGTATGCCTGC 321 AATATGGGAACAAATTAGAGGAGACTTTTTTTTTTCATGTTATGAGCTAGCACATACACCCCCTTGTAGTATAATTTCAA 401 GGAACTGTGTACGCCATTTATGGCATGATTAGATTGCAAAGCAATGAACTCAAGAAGGAATTGAAATAAGGAGGGACATG 481 ATGGGGAAGGAGTACAAAACAATCTCTCAACATGATTGAACCATTTGGGATGGAGAAGCACCTTTGCTCTCAGCCACCTG 561 TTACTAAGTCAGGAGTGTAGTTGGATCTCTACATTAATGTCCTCTTGCTGTCTACAGTAGCTGCTACCTAAAAAAAGATG 641 TTTTATTTTGCCAGTTGGACACAGGTGATTGGCTCCTGGGTTTCATGTTCTGTGACATCCTGCTTCTTCTTCCAAATGCA 721 GTTCATTGCAGACACCACCATATTGCTATCTAATGGGGAAATGTAGCTATGGGCCATAACCAAAACTCACATGAAACGGA 801 GGCAGATGGAGACCAAGGGTGGGATCCAGAATGGAGTCTTTTCTGTTATTGTATTTAAAAGGGTAATGTGGCCTTGGCAT 881 TTCTTCTTAGAAAAAAACTAATTTTTGGTGCTGATTGGCATGTCTGGTTCACAGTTTAGCATTGTTATAAACCATTCCAT 961 TCGAAAAGCACTTTGAAAAATTGTTCCCGAGCGATAGATGGGATGGTTTATGCAAGTCATGCTGAATACTCCTCCCCTCT 1041 TCTCTTTTGCCCCCTCCCTTCCTGCCCCCAGTCTGGGTTACTCTTCGCTTCTGGTATCTGGCGTTCTTTGGTACACAGTT 1121 CTGGTGTTCCTACCAGGACTCAAGAGACACCCCTTCCTGCTGACATTCCCATCACAACATTCCTCAGACAAGCCTGTAAA 1201 CTAAAATCTGTTACCATTCTGATGGCACAGAAGGATCTTAATTCCCATCTCTATACTTCTCCTTTGGACATGGAAAGAAA 1281 AGTTATTGCTGGTGCAAAGATAGATGGCTGAACATCAGGGTGTGGCATTTTGTTCCCTTTTCCGTTTTTTTTTTTTTATT 1361 GTTGTTGTTAATTTTATTGCAAAGTTGTATTCAGCGTACTTGAATTTTTCTTCCTCTCCACTTCTTAGAGGCATTCAGTT 1441 AGCAAAGAGGTTGGAGCAACAACTTTTTTTTTTTTTTTTGCACAATTGTAATTGACAGGTAATGAAGCTATTTGTTAAAA 1521 TATTTGCCTTTTTAAGTAAAAAAGAAAAATCAGAACAGGGCTATTTGAAGAATTATTTTATACACAGATTCTGCCTTGTT 1601 TCATAGTATGAGGGTTGAAGACGGAAAACAATCTAAGGGTCTCTCATTTTTTTAATTTTGTTTTGTTCAGTTTGGTTTTT 1681 TTTTTTTTTTGCGCTGCTAAGAAGCTAAAGTCATCCATCCTTATTCACGTTGACAGTACCTAGCTGTAATGTTTCACAGA 1761 GTGTGCTGCTATTTTATAAACATTTTTATAATATATTATTTTACTGCTTAAATTCCAAGTCCTGAAGTAGATGGTTGAGA 1841 TATGAGTTCTTCGTACTGGAAAAGCCCTTCCGTAGTTTGTTTTCTTCTGGTAGCATATTCATGGTTGTTTTTTTTTTTCT 1921 TTTTTGGTTTTTTGGTTTTTTTTTTTTCCTCTGATCACATTCTTCAAAGACGGAGTATTCTTTACCTCAGGTTTACTGGA 2001 CAAAATCAATAACTACAAAAGGCAATGATTCACGCTTTTGTTTTCATAATACCTCACAACCGTACAGTTTCTGCTTGGGA 2081 GCCCATTCGCATGAGGAATACAGAAGCAGTGTGAGCAGGGCTGACTCCCTCTCAGGTGGAAGGCAGGGCGGTCTCACTCC 2161 CAGGGACCTTTTTGGTCATGGAGGCCATCGGGCTCCCAGTTAGACCCTGGTATCCTCATCATGATGGAAAAAATACATTG 2241 AACCAAGGGATCCTCCCTCCCCTTCAAGGCAGACGTTCAGTACAAACATTTATGCGGTAGGCTCAGATGTCGTAATTTGC 2321 ACTTAGGTACCAGGTGTCAGGAAACAGACTAAAAAGAATTCCACCAGGCTGTTTGGAGATCCTCATCTTGGAGCTTTTTC 2401 AAAAGCGGGGCTTCATCTGCAAAGGGCCCTTTCATCTTGAAGTTTTTCCCCTCCGTCTTTCCCCTCCCCTGGCATGGACA 2481 CCTTGTGTTTAGGATCATCTCTGCAGGTTTCCTAGGTCTGAATCTGCGAGTAGATGAACCTGCAGCAAGCAGCGTTTATG 2561 GTGCTTCCTTCTCCCTCCTCTGTCTCAAACTGCGCAGGCAAGCACTATGCAAGCCCAGGCCCTCTGCTGAGCGGTACTAA 2641 ACGGTCGGGTTTTCAATCACACTGAATTGGCAGGATAAGAAAAATAGGTCAGATAAGTATGGGATGATAGTTGAAGGGAG 2721 GTGAAGAGGCTGCTTCTCTACAGAGGTGAAATTCCAGATGAGTCAGTCTCTTGGGAAGTGTGTTTAGAAGGGTTCAGGAC 2801 TTTGTGAGTTAGCATGACCCTAAAATTCTAGGGGATTTCTGGTGGGACAATGGGTGGTGAATTCTGAAGTTTTGGAGAGG 2881 GAAGTGGAGCAGCCAGCAAGTAAGCTAGCCAGAGTTTTCTCAAGAGCCAGCTTTGCTCAGCACACTCTCCTGGGCCCCAA 2961 GGAGTCCCACGGAATGGGGAAAGCGGGAACCCTGGAGTTCTTGGGAATCTTGGAGCCTAAAGAGAAACCGAGGTGCAAAT 3041 TCATTTCATGGTGACTGACCCTTGAGCTTAAACAGAAGCAGCAAATGAAAGAACCGGACAAATAAGGAAGGGCACAAGCC 3121 TACCCGACTCTATTTACAGTCTGTAACTTTCCACTCTTCCTGTAGTCCCGAGGCCCCTGGGTCCTTCTAGCTTTTCTCTT 3201 TCCCATCCTTGGGGCCTTGTGTGATGATGGGTGTGGGGCTGCCGATGGGAAAGTCGGGGGTTGTTAGGCTTTTCTGCCTG 3281 CTCCTGCTTAAACACAAGAAGGAATCCTGGATTTTGCCCTCTCCTTAGCTCTTAGTCTCTTTGGTAGGAGTTTTGTTCCA 3361 GAGGAGCTCTCCCCCTTGGATTTGAACTTGCTCTTTTTGTTGTTGTTGTTCTTTCTCTTCTTTTTCTTACCTCCCACTAA 3441 AGGGGTTCCAAATTATCCTGGTCTTTTTCTACCTTGTTGTGTTTCTATCTCGTCTTTACTTCCATCTGTTTGTTTTTTTC 3521 TCCATCAGTGGGGGCCGAGTTGTTCCCCCAGCCTGCCAAATTTTGATCCTTCCCCTCTTTTGGCCAAATCCTAGGGGGAA 3601 GAAATCCTAGTATGCCAAAAATATATGCTAAGCATAATTAAACTCCATGCGGGTCCATAACAGCCAAGAAGCCTGCAGGA 3681 GAAAGCCAAGGGCAGTTCCCTCCGCAGAACACCCCATGCGTGCTGAGAGGCGAGCTCCTTGAAGAAGGGGCTGTTCTTCC 3761 AGGAGGCCTTATTTTGAACTGCCTCAGGACCCCACTGGAGAGCACAGCATGCCTTACTACTGGGTCATCCTTGGTCTATG 3841 TGCTCTGTACTGGAGGCTCTGTTCTGCCTCTTATCAGCCAGGTCAGGGGCACACATGGCTTAAGTGACAAAGCCAGAGGA 3921 GAAGACAACCCTGACAGCATCACGCTGCATCCCATTGCTAGCAGGATTGGCAACTCTTCAGACGGAGCTGCGCTTCCCTG 4001 CAGTCTAGCACCTCTAGGGCCTCTCCAGACTGTGCCCTGGGAGCTCTGGGACTGAAAGGTTAAGAACATAAGGCAGGATC 4081 AGATGACTCTCTCCAAGAGGGCAGGGGAATTTTCTCTCCATGGGCCACAGGGGACAGGGCTGGGAGAAGAAATAGACTTG 4161 CACCTTATGTCATGTAAATAATTGATTTTCTAGTTCAAGAAGATAATATTGGTAGTGTGGGAATTGGAGGTAGGAAGGGG 4241 AGGAAGTCTGAGTAAGCCAGTTGGCTTCTAAGCCAAAAGGATTCCTCTTTGTTTATCTCTGAGACAGTCCAACCTTGAGA 4321 ATAGCTTTAAAAGGGAAATTAATGCTGAGATGATAAAGTCCCCTTAAGCCAACAAACCCTCTGTAGCTATAGAATGAGTG 4401 CAGGTTTCTATTGGTGTGGACTCAGAGCAATTTACAAGAGCTGTTCATGCAGCCATCCATTTGTGCAAAATAGGGTAAGA 4481 AGATTCAAGAGGATATTTATTACTTCCTCATACCACATGGCTTTTGATGATTCTGGATTCTAAACAACCCAGAATGGTCA 4561 TTTCAGGCACAACGATACTACATTCGTGTGTGTCTGCTTTTAAACTTGGCTGGGCTATCAGACCCTATTCTCGGCTCAGG 4641 TTTTGAGAAGCCATCAGCAAATGTGTACGTGCATGCTGTAGCTGCAGCCTGCATCCCTTCGCCTGCAGCCTACTTTGGGG 4721 AAATAAAGTGCCTTACTGACTGTAGCCATTACAGTATCCAATGTCTTTTGACAGGTGCCTGTCCTTGAAAAACAAAGTTT 4801 CTATTTTTATTTTTAATTGGTTTAGTTCTTAACTGCTGGCCAACTCTTACATCCCCAGCAAATCATCGGGCCATTGGATT 4881 TTTTCCATTATGTTCATCACCCTTATATCATGTACCTCAGATCTCTCTCTCTCTCCTCTCTCTCAGTTATGTAGTTTCTT 4961 GTCTTGGACTTTTTTTTTTCTTTTCTTTTTCTTTTTTTTTTTGCTTTAAAACAAGTGTGATGCCATATCAAGTCCATGTT 5041 ATTCTCTCACAGTGTACTCTATAAGAGGTGTGGGTGTCTGTTTGGTCAGGATGTTAGAAAGTGCTGATAAGTAGCATGAT 5121 CAGTGTATGCGAAAAGGTTTTTAGGAAGTATGGCAAAAATGTTGTATTGGCTATGATGGTGACATGATATAGTCAGCTGC 5201 CTTTTAAGAGGTCTTATCTGTTCAGTGTTAAGTGATTTAAAAAAATAATAACCTGTTTTCTGACTAGTTTAAAGATGGAT 5281 TTGAAAATGGTTTTGAATGCAATTAGGTTATGCTATTTGGACAATAAACTCACCTTGACCTAAATTAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
DRVs in gene 3'UTRs |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SNPs in gene 3'UTRs |
|
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Bandi N; Zbinden S; Gugger M; Arnold M; et al. - Cancer research, 2009
MicroRNAs (miRNA) are negative regulators of gene expression at the posttranscriptional level, which are involved in tumorigenesis. Two miRNAs, miR-15a and miR-16, which are located at chromosome 13q14, have been implicated in cell cycle control and apoptosis, but little information is available about their role in solid tumors. To address this question, we established a protocol to quantify miRNAs from laser capture microdissected tissues. Here, we show that miR-15a/miR-16 are frequently deleted or down-regulated in squamous cell carcinomas and adenocarcinomas of the lung. In these tumors, expression of miR-15a/miR-16 inversely correlates with the expression of cyclin D1. In non-small cell lung cancer (NSCLC) cell lines, cyclins D1, D2, and E1 are directly regulated by physiologic concentrations of miR-15a/miR-16. Consistent with these results, overexpression of these miRNAs induces cell cycle arrest in G(1)-G(0). Interestingly, H2009 cells lacking Rb are resistant to miR-15a/miR-16-induced cell cycle arrest, whereas reintroduction of functional Rb resensitizes these cells to miRNA activity. In contrast, down-regulation of Rb in A549 cells by RNA interference confers resistance to these miRNAs. Thus, cell cycle arrest induced by these miRNAs depends on the expression of Rb, confirming that G(1) cyclins are major targets of miR-15a/miR-16 in NSCLC. Our results indicate that miR-15a/miR-16 are implicated in cell cycle control and likely contribute to the tumorigenesis of NSCLC.
LinkOut: [PMID: 19549910]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1, repA
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Liu YL; Yang HP; Zhou XD; Gong L; Tang CL; Wang HJ - Current cancer drug targets, 2011
Hypermethylation of the Wnt inhibitory factor-1 (WIF-1) promoter has been implicated in the overactivation of the Wnt pathway in human lung cancer. Curcuminoids exert anti-cancer effects and have been reported to act as hypomethylating agents. Previously, we have investigated and compared the demethylation effects of three curcuminoids and observed that bisdemethoxycurcumin exhibited the strongest demethylation potency. In this study, we used lung cancer cell lines with WIF-1 promoter hypermethylated as a model to study the demethylating effect of bisdemethoxycurcumin on WIF-1 restoration, Wnt signaling activity and cell death. Bisdemethoxycurcumin directly suppressed the activity of DNA methyltransferase-1 (DNMT1) but did not influence DNMT1 expression. In addition, it induced WIF-1 promoter demethylation and protein re-expression. WIF-1 restoration in lung cancer cells down-regulated nuclear beta-catenin and the canonical Wnt cascade. Furthermore, we also showed that down-regulation of Wnt signaling by WIF-1 was required for bisdemethoxycurcumin-induced apoptosis in certain lung cancer cell types. This report is the first to show that bisdemethoxycurcumin induces apoptosis by reactivating WIF-1 from a silenced state. Our results provide new insights into the anti-cancer actions of bisdemethoxycurcumin.
LinkOut: [PMID: 21933103]
|
Experimental Support 5 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Flp-In T-REx 293-hAGO1 cells |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
Validation of interactions identified by CLASH suppports their reliability.
... - Helwak A; Kudla G; Dudnakova T; Tollervey D, 2013, Cell. |
Article |
- Helwak A; Kudla G; Dudnakova T; Tollervey D - Cell, 2013
MicroRNAs (miRNAs) play key roles in gene regulation, but reliable bioinformatic or experimental identification of their targets remains difficult. To provide an unbiased view of human miRNA targets, we developed a technique for ligation and sequencing of miRNA-target RNA duplexes associated with human AGO1. Here, we report data sets of more than 18,000 high-confidence miRNA-mRNA interactions. The binding of most miRNAs includes the 5' seed region, but around 60% of seed interactions are noncanonical, containing bulged or mismatched nucleotides. Moreover, seed interactions are generally accompanied by specific, nonseed base pairing. 18% of miRNA-mRNA interactions involve the miRNA 3' end, with little evidence for 5' contacts, and some of these were functionally validated. Analyses of miRNA:mRNA base pairing showed that miRNA species systematically differ in their target RNA interactions, and strongly overrepresented motifs were found in the interaction sites of several miRNAs. We speculate that these affect the response of RISC to miRNA-target binding.
LinkOut: [PMID: 23622248]
|
CLIP-seq Support 1 for dataset GSM545216 | |
Method / RBP | PAR-CLIP / AGO2 |
---|---|
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000261254.3 | 3UTR | UGCUGCUAUUUUAUAAACAUUUUUAUAAUAUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM714644 | |
Method / RBP | PAR-CLIP / AGO2 |
---|---|
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000261254.3 | 3UTR | UGCUGCUAUUUUAUAAACAUUUUUAUAAUAUAUUAUUUUACUGCUUAAAUUCCAAGUCCUGAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT000280 | BMI1 | BMI1 proto-oncogene, polycomb ring finger | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 3 | |||
MIRT000282 | WNT3A | Wnt family member 3A | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT000283 | MYB | MYB proto-oncogene, transcription factor | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 3 | |||
MIRT000284 | CDC25A | cell division cycle 25A | ![]() |
![]() |
![]() |
3 | 3 | |||||
MIRT000285 | CCND2 | cyclin D2 | ![]() |
![]() |
![]() |
3 | 5 | |||||
MIRT000804 | RAB9B | RAB9B, member RAS oncogene family | ![]() |
1 | 1 | |||||||
MIRT000806 | ACTR1A | ARP1 actin related protein 1 homolog A | ![]() |
1 | 1 | |||||||
MIRT000808 | TPI1 | triosephosphate isomerase 1 | ![]() |
1 | 1 | |||||||
MIRT000810 | PDCD4 | programmed cell death 4 | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT000812 | RAB21 | RAB21, member RAS oncogene family | ![]() |
![]() |
2 | 1 | ||||||
MIRT000815 | BCL2 | BCL2, apoptosis regulator | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6 | 13 | ||
MIRT000817 | WT1 | Wilms tumor 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000819 | ASXL2 | additional sex combs like 2, transcriptional regulator | ![]() |
![]() |
2 | 1 | ||||||
MIRT000823 | TMEM251 | transmembrane protein 251 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000825 | CARD8 | caspase recruitment domain family member 8 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000827 | CDC14B | cell division cycle 14B | ![]() |
![]() |
2 | 1 | ||||||
MIRT000829 | CENPJ | centromere protein J | ![]() |
![]() |
2 | 1 | ||||||
MIRT000831 | CEP63 | centrosomal protein 63 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000833 | CREBL2 | cAMP responsive element binding protein like 2 | ![]() |
![]() |
![]() |
3 | 3 | |||||
MIRT000835 | ECHDC1 | ethylmalonyl-CoA decarboxylase 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000847 | GOLGA5 | golgin A5 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000849 | GOLPH3L | golgi phosphoprotein 3 like | ![]() |
![]() |
2 | 1 | ||||||
MIRT000851 | GTF2H1 | general transcription factor IIH subunit 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000853 | H3F3B | H3 histone family member 3B | ![]() |
![]() |
2 | 1 | ||||||
MIRT000855 | HACE1 | HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000857 | HDHD2 | haloacid dehalogenase like hydrolase domain containing 2 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000859 | HERC6 | HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000863 | HRSP12 | reactive intermediate imine deaminase A homolog | ![]() |
![]() |
2 | 1 | ||||||
MIRT000865 | HSDL2 | hydroxysteroid dehydrogenase like 2 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000866 | HSPA1A | heat shock protein family A (Hsp70) member 1A | ![]() |
![]() |
2 | 1 | ||||||
MIRT000868 | JUN | Jun proto-oncogene, AP-1 transcription factor subunit | ![]() |
![]() |
2 | 1 | ||||||
MIRT000878 | MCL1 | MCL1, BCL2 family apoptosis regulator | ![]() |
![]() |
2 | 1 | ||||||
MIRT000880 | MSH2 | mutS homolog 2 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000884 | OMA1 | OMA1 zinc metallopeptidase | ![]() |
![]() |
2 | 1 | ||||||
MIRT000886 | OSGEPL1 | O-sialoglycoprotein endopeptidase like 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000888 | PDCD6IP | programmed cell death 6 interacting protein | ![]() |
![]() |
2 | 1 | ||||||
MIRT000890 | PHKB | phosphorylase kinase regulatory subunit beta | ![]() |
![]() |
2 | 1 | ||||||
MIRT000892 | PMS1 | PMS1 homolog 1, mismatch repair system component | ![]() |
![]() |
2 | 1 | ||||||
MIRT000894 | PNN | pinin, desmosome associated protein | ![]() |
![]() |
2 | 1 | ||||||
MIRT000896 | PRIM1 | DNA primase subunit 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000898 | RAD51C | RAD51 paralog C | ![]() |
![]() |
2 | 1 | ||||||
MIRT000900 | RHOT1 | ras homolog family member T1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000902 | RNASEL | ribonuclease L | ![]() |
![]() |
2 | 1 | ||||||
MIRT000906 | SLC35A1 | solute carrier family 35 member A1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000908 | SLC35B3 | solute carrier family 35 member B3 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000910 | TIA1 | TIA1 cytotoxic granule associated RNA binding protein | ![]() |
![]() |
2 | 1 | ||||||
MIRT000914 | UGDH | UDP-glucose 6-dehydrogenase | ![]() |
![]() |
2 | 1 | ||||||
MIRT000916 | UGP2 | UDP-glucose pyrophosphorylase 2 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000922 | ZNF559 | zinc finger protein 559 | ![]() |
![]() |
2 | 1 | ||||||
MIRT001227 | CCND1 | cyclin D1 | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 7 | |||
MIRT001228 | CCNE1 | cyclin E1 | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6 | 8 | ||
MIRT001802 | BACE1 | beta-secretase 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT002946 | DMTF1 | cyclin D binding myb like transcription factor 1 | ![]() |
![]() |
![]() |
3 | 3 | |||||
MIRT003333 | BRCA1 | BRCA1, DNA repair associated | ![]() |
![]() |
2 | 2 | ||||||
MIRT003334 | AKT3 | AKT serine/threonine kinase 3 | ![]() |
![]() |
2 | 4 | ||||||
MIRT003872 | WIPF1 | WAS/WASL interacting protein family member 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003873 | VPS45 | vacuolar protein sorting 45 homolog | ![]() |
![]() |
2 | 1 | ||||||
MIRT003874 | HSP90B1 | heat shock protein 90 beta family member 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003875 | SKAP2 | src kinase associated phosphoprotein 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003876 | NT5DC1 | 5'-nucleotidase domain containing 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003877 | FAM69A | family with sequence similarity 69 member A | ![]() |
![]() |
2 | 1 | ||||||
MIRT003878 | C2orf74 | chromosome 2 open reading frame 74 | ![]() |
1 | 1 | |||||||
MIRT003879 | FAM122C | family with sequence similarity 122C | ![]() |
![]() |
2 | 1 | ||||||
MIRT003880 | PWWP2A | PWWP domain containing 2A | ![]() |
![]() |
2 | 1 | ||||||
MIRT003881 | C17orf80 | chromosome 17 open reading frame 80 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003882 | CCDC111 | primase and DNA directed polymerase | ![]() |
![]() |
2 | 1 | ||||||
MIRT003883 | C2orf43 | lipid droplet associated hydrolase | ![]() |
![]() |
2 | 1 | ||||||
MIRT003884 | C4orf27 | histone PARylation factor 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003885 | NIPAL2 | NIPA like domain containing 2 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003886 | TRMT13 | tRNA methyltransferase 13 homolog | ![]() |
![]() |
2 | 1 | ||||||
MIRT003887 | ANAPC16 | anaphase promoting complex subunit 16 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003888 | CADM1 | cell adhesion molecule 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003891 | TMEM184B | transmembrane protein 184B | ![]() |
![]() |
2 | 1 | ||||||
MIRT003899 | APP | amyloid beta precursor protein | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT004046 | UCP2 | uncoupling protein 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT004275 | VEGFA | vascular endothelial growth factor A | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6 | 11 | ||
MIRT004680 | TSPYL2 | TSPY like 2 | ![]() |
![]() |
2 | 1 | ||||||
MIRT004829 | NFKB1 | nuclear factor kappa B subunit 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT005552 | CHUK | conserved helix-loop-helix ubiquitous kinase | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT005763 | TP53 | tumor protein p53 | ![]() |
1 | 1 | |||||||
MIRT006027 | FGF7 | fibroblast growth factor 7 | ![]() |
![]() |
2 | 1 | ||||||
MIRT006176 | CLCN3 | chloride voltage-gated channel 3 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT006177 | CRKL | CRK like proto-oncogene, adaptor protein | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 2 | |||
MIRT006181 | MN1 | MN1 proto-oncogene, transcriptional regulator | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT006658 | Ccnd1 | cyclin D1 | ![]() |
1 | 1 | |||||||
MIRT006801 | HMGA1 | high mobility group AT-hook 1 | ![]() |
![]() |
![]() |
![]() |
4 | 2 | ||||
MIRT006805 | HMGA2 | high mobility group AT-hook 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT006913 | IFNG | interferon gamma | ![]() |
![]() |
2 | 1 | ||||||
MIRT006998 | PURA | purine rich element binding protein A | ![]() |
![]() |
2 | 2 | ||||||
MIRT007090 | RECK | reversion inducing cysteine rich protein with kazal motifs | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT032077 | DLK1 | delta like non-canonical Notch ligand 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT051311 | PLA2G2D | phospholipase A2 group IID | ![]() |
1 | 1 | |||||||
MIRT051312 | ACVR1B | activin A receptor type 1B | ![]() |
1 | 1 | |||||||
MIRT051313 | IKBKG | inhibitor of nuclear factor kappa B kinase subunit gamma | ![]() |
1 | 1 | |||||||
MIRT051314 | GCLM | glutamate-cysteine ligase modifier subunit | ![]() |
1 | 1 | |||||||
MIRT051315 | PCF11 | PCF11 cleavage and polyadenylation factor subunit | ![]() |
1 | 1 | |||||||
MIRT051316 | HIST1H2BK | histone cluster 1 H2B family member k | ![]() |
1 | 1 | |||||||
MIRT051317 | ODC1 | ornithine decarboxylase 1 | ![]() |
1 | 1 | |||||||
MIRT051318 | CALD1 | caldesmon 1 | ![]() |
1 | 1 | |||||||
MIRT051319 | RPP30 | ribonuclease P/MRP subunit p30 | ![]() |
1 | 1 | |||||||
MIRT051320 | ASNSD1 | asparagine synthetase domain containing 1 | ![]() |
1 | 1 | |||||||
MIRT051321 | CCNYL1 | cyclin Y like 1 | ![]() |
1 | 1 | |||||||
MIRT051322 | RGPD5 | RANBP2-like and GRIP domain containing 5 | ![]() |
1 | 1 | |||||||
MIRT051323 | PREB | prolactin regulatory element binding | ![]() |
1 | 1 | |||||||
MIRT051324 | PDHX | pyruvate dehydrogenase complex component X | ![]() |
1 | 1 | |||||||
MIRT051325 | SNX6 | sorting nexin 6 | ![]() |
1 | 1 | |||||||
MIRT051326 | CNN3 | calponin 3 | ![]() |
1 | 1 | |||||||
MIRT051327 | KIF1A | kinesin family member 1A | ![]() |
1 | 1 | |||||||
MIRT051328 | NAB1 | NGFI-A binding protein 1 | ![]() |
1 | 1 | |||||||
MIRT051329 | CCT6B | chaperonin containing TCP1 subunit 6B | ![]() |
1 | 1 | |||||||
MIRT051330 | CHD4 | chromodomain helicase DNA binding protein 4 | ![]() |
1 | 1 | |||||||
MIRT051331 | CLCC1 | chloride channel CLIC like 1 | ![]() |
1 | 1 | |||||||
MIRT051332 | GDI2 | GDP dissociation inhibitor 2 | ![]() |
1 | 1 | |||||||
MIRT051333 | BRWD1 | bromodomain and WD repeat domain containing 1 | ![]() |
1 | 1 | |||||||
MIRT051334 | MAPK6 | mitogen-activated protein kinase 6 | ![]() |
1 | 1 | |||||||
MIRT051335 | PSMC4 | proteasome 26S subunit, ATPase 4 | ![]() |
1 | 1 | |||||||
MIRT051336 | ATF2 | activating transcription factor 2 | ![]() |
1 | 1 | |||||||
MIRT051337 | ATP6AP1 | ATPase H+ transporting accessory protein 1 | ![]() |
1 | 1 | |||||||
MIRT051338 | FBXO3 | F-box protein 3 | ![]() |
1 | 1 | |||||||
MIRT051339 | PRDX3 | peroxiredoxin 3 | ![]() |
1 | 1 | |||||||
MIRT051340 | CABIN1 | calcineurin binding protein 1 | ![]() |
1 | 1 | |||||||
MIRT051341 | FASN | fatty acid synthase | ![]() |
1 | 3 | |||||||
MIRT051342 | SEC63 | SEC63 homolog, protein translocation regulator | ![]() |
1 | 1 | |||||||
MIRT051343 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 | ![]() |
1 | 1 | |||||||
MIRT051344 | DSTYK | dual serine/threonine and tyrosine protein kinase | ![]() |
1 | 1 | |||||||
MIRT051345 | FOXO1 | forkhead box O1 | ![]() |
![]() |
![]() |
![]() |
4 | 2 | ||||
MIRT051346 | TMEM214 | transmembrane protein 214 | ![]() |
1 | 1 | |||||||
MIRT051347 | TRIM28 | tripartite motif containing 28 | ![]() |
1 | 1 | |||||||
MIRT051348 | NOP2 | NOP2 nucleolar protein | ![]() |
1 | 1 | |||||||
MIRT051349 | MYBL1 | MYB proto-oncogene like 1 | ![]() |
1 | 1 | |||||||
MIRT051350 | TTC1 | tetratricopeptide repeat domain 1 | ![]() |
1 | 1 | |||||||
MIRT051351 | BTRC | beta-transducin repeat containing E3 ubiquitin protein ligase | ![]() |
1 | 2 | |||||||
MIRT052930 | REPIN1 | replication initiator 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT053079 | KLF4 | Kruppel like factor 4 | ![]() |
1 | 1 | |||||||
MIRT054283 | YAP1 | Yes associated protein 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054424 | CARM1 | coactivator associated arginine methyltransferase 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054895 | SOX5 | SRY-box 5 | ![]() |
![]() |
2 | 1 | ||||||
MIRT055421 | SHOC2 | SHOC2, leucine rich repeat scaffold protein | ![]() |
1 | 6 | |||||||
MIRT055811 | PLEKHA1 | pleckstrin homology domain containing A1 | ![]() |
1 | 1 | |||||||
MIRT057514 | CEP55 | centrosomal protein 55 | ![]() |
1 | 4 | |||||||
MIRT057729 | ZDHHC16 | zinc finger DHHC-type containing 16 | ![]() |
1 | 1 | |||||||
MIRT057906 | STXBP3 | syntaxin binding protein 3 | ![]() |
1 | 1 | |||||||
MIRT061005 | C1ORF21 | chromosome 1 open reading frame 21 | ![]() |
1 | 3 | |||||||
MIRT061244 | AMOTL1 | angiomotin like 1 | ![]() |
1 | 6 | |||||||
MIRT061529 | BTG2 | BTG anti-proliferation factor 2 | ![]() |
1 | 1 | |||||||
MIRT063394 | ETNK1 | ethanolamine kinase 1 | ![]() |
1 | 1 | |||||||
MIRT065711 | TARBP2 | TARBP2, RISC loading complex RNA binding subunit | ![]() |
1 | 2 | |||||||
MIRT066291 | MTFR1L | mitochondrial fission regulator 1 like | ![]() |
1 | 1 | |||||||
MIRT066312 | USP15 | ubiquitin specific peptidase 15 | ![]() |
1 | 1 | |||||||
MIRT068655 | AKAP11 | A-kinase anchoring protein 11 | ![]() |
1 | 1 | |||||||
MIRT071206 | FCF1 | FCF1, rRNA-processing protein | ![]() |
1 | 1 | |||||||
MIRT072822 | ARIH1 | ariadne RBR E3 ubiquitin protein ligase 1 | ![]() |
1 | 3 | |||||||
MIRT074530 | PAGR1 | PAXIP1 associated glutamate rich protein 1 | ![]() |
1 | 2 | |||||||
MIRT075249 | SNTB2 | syntrophin beta 2 | ![]() |
1 | 2 | |||||||
MIRT075273 | VPS4A | vacuolar protein sorting 4 homolog A | ![]() |
1 | 4 | |||||||
MIRT075891 | C16ORF72 | chromosome 16 open reading frame 72 | ![]() |
1 | 4 | |||||||
MIRT076791 | GOSR1 | golgi SNAP receptor complex member 1 | ![]() |
1 | 1 | |||||||
MIRT077781 | MINK1 | misshapen like kinase 1 | ![]() |
1 | 1 | |||||||
MIRT078282 | RPS6KB1 | ribosomal protein S6 kinase B1 | ![]() |
1 | 1 | |||||||
MIRT079655 | NAPG | NSF attachment protein gamma | ![]() |
1 | 6 | |||||||
MIRT080011 | GALNT1 | polypeptide N-acetylgalactosaminyltransferase 1 | ![]() |
1 | 2 | |||||||
MIRT082985 | PNPLA6 | patatin like phospholipase domain containing 6 | ![]() |
1 | 1 | |||||||
MIRT083265 | ZCCHC3 | zinc finger CCHC-type containing 3 | ![]() |
1 | 3 | |||||||
MIRT084462 | SOWAHC | sosondowah ankyrin repeat domain family member C | ![]() |
1 | 2 | |||||||
MIRT085215 | CCNT2 | cyclin T2 | ![]() |
1 | 1 | |||||||
MIRT086005 | UBR3 | ubiquitin protein ligase E3 component n-recognin 3 (putative) | ![]() |
1 | 1 | |||||||
MIRT087424 | ZNRF3 | zinc and ring finger 3 | ![]() |
1 | 1 | |||||||
MIRT087554 | YWHAH | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta | ![]() |
1 | 1 | |||||||
MIRT088102 | SEPT2 | septin 2 | ![]() |
1 | 1 | |||||||
MIRT089105 | B3GNT2 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 | ![]() |
1 | 2 | |||||||
MIRT089206 | ACTR2 | ARP2 actin related protein 2 homolog | ![]() |
1 | 2 | |||||||
MIRT090446 | CDV3 | CDV3 homolog | ![]() |
1 | 1 |